UnitedHealthcare has delayed its planned policy limiting coverage for remote physiologic monitoring (RPM) to heart failure and hypertensive disorders of pregnancy, which was initially set to begin in January 2026. This controversial decision has drawn criticism for contradicting existing scientific evidence that supports the benefits of RPM for various conditions, such as anxiety, COPD, diabetes, and obstructive sleep apnea. Health experts warn that restricting coverage may hinder advancements in managing cardiovascular diseases and might negatively impact patient care. As RPM adoption grows—particularly within Medicare—healthcare professionals must closely monitor these developments to advocate for effective technologies that improve patient outcomes.
